S100P, von Hippel-Lindau gene product, and IMP3 serve as a useful immunohistochemical panel in the diagnosis of adenocarcinoma on endoscopic bile duct biopsy

Human Pathology

Volumn 41, Issue 9, 2010, Pages 1210-1219

  Levy, Mary ^a   Lin, Fan ^b   Xu, Haodong ^c   Dhall, Deepti ^a   Spaulding, Betsy O ^d   Wang, Hanlin L ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

^c UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^d AGILENT TECHNOLOGIES   (United States)

Author keywords

Adenocarcinoma; Bile duct; Biopsy; IMP3; PVHL; S100P

Indexed keywords

GENE PRODUCT; INSULIN LIKE GROWTH FACTOR II MESSENGER RNA BINDING PROTEIN 3; ONCOPROTEIN; PROTEIN S 100; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BILE DUCT; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CELL NUCLEUS; CYTOPLASM; DIAGNOSTIC VALUE; DYSPLASIA; ENDOSCOPIC BIOPSY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOPSY; CARCINOMA, PANCREATIC DUCTAL; CARRIER PROTEINS; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PRECANCEROUS CONDITIONS; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77955097264     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.01.014     Document Type: Article

References (36)

1. Allen P.J., Reiner A.S., and Gonen M. Extrahepatic cholangiocarcinoma: a comparison of patients with resected proximal and distal lesions HPB Surg 10 2008 341 346
2. Carpelan-Holmström M., Nordling S., and Pukkala E. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry Gut 54 2005 385 387
3. Fitzgerald T.L., Hickner Z.J., and Schmitz M. Changing incidence of pancreatic neoplasms: a 16-year review of statewide tumor registry Pancreas 37 2008 134 138
4. Khan S.A., Toledano M.B., and Taylor-Robinson S.D. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma HPB Surg 10 2008 77 82
5. Shaib Y., and El-Serag H.B. The epidemiology of cholangiocarcinoma Semin Liver Dis 24 2004 115 125
6. Sohn T.A., Yeo C.J., and Cameron J.L. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators J Gastrointest Surg 4 2000 567 579
7. Tan G., Yilmaz A., and De Young B.R. Immunohistochemical analysis of biliary tract lesions Appl Immunohistochem Mol Morphol 12 2004 193 197
8. Karamitopoulou E., Tornillo L., and Zlobec I. Clinical significance of cell cycle- and apoptosis-related markers in biliary tract cancer: a tissue microarray-based approach revealing a distinctive immunophenotype for intrahepatic and extrahepatic cholangiocarcinomas Am J Clin Pathol 130 2008 780 786
9. Agrawal S., Kuvshinoff B.W., and Khoury T. CD24 expression is an independent prognostic marker in cholangiocarcinoma J Gastrointest Surg 11 2007 445 451
10. Argani P., Iacobuzio-Donahue C., and Ryu B. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE) Clin Cancer Res 7 2001 3862 3868
11. Hassan R., Laszik Z.G., and Lerner M. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis Am J Clin Pathol 124 2005 838 845
12. Javle M.M., Tan D., and Yu J. Nuclear survivin expression predicts poor outcome in cholangiocarcinoma Hepatogastroenterology 51 2004 1653 1657
13. Obama K., Ura K., and Li M. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma Hepatology 41 2005 1339 1348
14. Su M.C., Hsu C., and Kao H.L. CD24 expression is a prognostic factor in intrahepatic cholangiocarcinoma Cancer Lett 235 2006 34 39
15. Swierczynski S.L., Maitra A., and Abraham S.C. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays Hum Pathol 35 2004 357 366
16. Tascilar M., Offerhaus G.J., and Altink R. Immunohistochemical labeling for the Dpc4 gene product is a specific marker for adenocarcinoma in biopsy specimens of the pancreas and bile duct Am J Clin Pathol 116 2001 831 837
17. Zhao H., Davydova L., and Mandich D. S100A4 protein and mesothelin expression in dysplasia and carcinoma of the extrahepatic bile duct Am J Clin Pathol 127 2007 374 379
18. Lin F., Shi J., and Liu H. Diagnostic utility of S100P and von Hippel-Lindau gene product (pVHL) in pancreatic adenocarcinoma-with implication of their roles in early tumorigenesis Am J Surg Pathol 32 2008 78 91
19. Xu H. IMP3: a diagnostic and prognostic biomarker in malignant melanoma Expert Rev Mol Diagn 8 2008 557 558
20. Yantiss R.K., Cosar E., and Fischer A.H. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas Acta Cytol 52 2008 133 138
21. Yantiss R.K., Woda B.A., and Fanger G.R. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas Am J Surg Pathol 29 2005 188 195
22. Zhao H., Mandich D., and Cartun R.W. Expression of K homology domain containing protein overexpressed in cancer in pancreatic FNA for diagnosing adenocarcinoma of pancreas Diagn Cytopathol 35 2007 700 704
23. Ligato S., Zhao H., and Mandich D. KOC (K homology domain containing protein overexpressed in cancer) and S100A4-protein immunoreactivity improves the diagnostic sensitivity of biliary brushing cytology for diagnosing pancreaticobiliary malignancies Diagn Cytopathol 36 2008 561 567
24. Pryor J.G., Bourne P.A., and Yang Q. IMP-3 is a novel progression marker in malignant melanoma Mod Pathol 21 2008 431 437
25. 2+ binding properties Eur J Biochem 207 1992 541 547
26. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles Int J Biochem Cell Biol 33 2001 637 668
27. Parkkila S., Pan P.W., and Ward A. The calcium-binding protein S100P in normal and malignant human tissues BMC Clin Pathol 8 2008 2
28. Deng H., Shi J., and Wilkerson M. Usefulness of S100P in diagnosis of adenocarcinoma of pancreas on fine-needle aspiration biopsy specimens Am J Clin Pathol 129 2008 81 88
29. Dowen S.E., Crnogorac-Jurcevic T., and Gangeswaran R. Expression of S100P and its novel binding partner S100PBPR in early pancreatic cancer Am J Pathol 166 2005 81 92
30. Ohuchida K., Mizumoto K., and Egami T. S100P is an early developmental marker of pancreatic carcinogenesis Clin Cancer Res 12 2006 5411 5416
31. Whiteman H.J., Weeks M.E., and Dowen S.E. The role of S100P in the invasion of pancreatic cancer cells is mediated through cytoskeletal changes and regulation of cathepsin D Cancer Res 67 2007 8633 8642
32. Sato N., Fukushima N., and Matsubayashi H. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling Oncogene 23 2004 1531 1538
33. Clark P.E., and Cookson M.S. The von Hippel-Lindau gene: turning discovery into therapy Cancer 113 Suppl 2008 1768 1778
34. 19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation Proc Natl Acad Sci USA 95 1998 11661 11666
35. Kaelin W.G. Von Hippel-Lindau disease Annu Rev Pathol 2 2007 145 173
36. Lin F., Shi J., and Liu H. Immunohistochemical detection of the von Hippel-Lindau gene product (pVHL) in human tissues and tumors: a useful marker for metastatic renal cell carcinoma and clear cell carcinoma of the ovary and uterus Am J Clin Pathol 129 2008 592 605